Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT

Machnowska, PatrycjaBusingye, PriscillaRubaihayo, JohnTheuring, Stefanie2025-05-072025-05-072017-05-31Machnowska, P., Hauser, A., Meixenberger, K., Altmann, B., Bannert, N., Rempis, E., ... & Theuring, S. (2017). Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT. PLoS One, 12(5), e0178297.https://doi.org/10.1371/journal.pone.0178297https://nru.uncst.go.ug/handle/123456789/11497Since 2012, WHO guidelines for the prevention of mother-to-child transmission (PMTCT) of HIV-1 in resource-limited settings recommend the initiation of lifelong antiretroviral combination therapy (cART) for all pregnant HIV-1 positive women independent of CD4 count and WHO clinical stage (Option B+). However, long-term outcomes regarding development of drug resistance are lacking until now. Therefore, we analysed the emergence of drug resistance mutations (DRMs) in women initiating Option B+ in Fort Portal, Uganda, at 12 and 18 months postpartum (ppm).enDecreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCTArticle